Sana Biotechnology, Inc. (SANA): Free Cash Flow
-$144.77M
Year ended 2025-12-31
-$135.06M
Trailing 12 months to 2026-06-30
| Period ended | Free Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$144.77M | n/m | 2026-03-03, From 2025-01-01 |
| 2024-12-31 | -$256.58M | n/m | 2026-03-03, From 2024-01-01 |
| 2023-12-31 | -$273.61M | n/m | 2026-03-03, From 2023-01-01 |
| 2022-12-31 | -$310.93M | n/m | 2025-03-17, From 2022-01-01 |
| 2021-12-31 | -$280.92M | n/m | 2024-02-29, From 2021-01-01 |
| 2020-12-31 | -$161.85M | n/m | 2023-03-16, From 2020-01-01 |
| 2019-12-31 | -$111.64M | n/a | 2022-03-16, From 2019-01-01 |
Free Cash Flow at similar companies
| Company | Year ended | Free Cash Flow | Change YoY |
|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | 2025-12-31 | -$144.77M | n/m |
| Allogene Therapeutics, Inc. (ALLO) | 2025-12-31 | -$149.63M | n/m |
| Scholar Rock Holding Corp (SRRK) | 2025-12-31 | -$300.64M | n/m |
| Maze Therapeutics, Inc. (MAZE) | 2025-12-31 | -$112.73M | n/m |
| Cullinan Therapeutics, Inc. (CGEM) | 2025-12-31 | -$175.80M | n/m |
| Monte Rosa Therapeutics, Inc. (GLUE) | 2025-12-31 | -$27.50M | n/m |
| REGENXBIO Inc. (RGNX) | 2025-12-31 | -$126.38M | n/m |
| Vor Biopharma Inc. (VOR) | 2025-12-31 | -$143.65M | n/m |
| Scilex Holding Co (SCLX) | 2025-12-31 | $3.68M | -81.0% |
Compare SANA, ALLO, SRRK, MAZE side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗